FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016741434> ?p ?o ?g. }

• W3016741434 endingPage "993" @default.
• W3016741434 startingPage "979" @default.
• W3016741434 abstract "Abstract Purpose Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this combination in patients with advanced solid tumor types for which tumor suppressor gene methylation is potentially prognostic. To obtain pharmacodynamic evidence for DNMT inhibition by FdCyd, we developed a novel method for detecting expression of tumor suppressor protein p16/INK4A in circulating tumor cells (CTCs). Methods Patients in histology-specific strata (breast, head and neck [H&N], or non-small cell lung cancers [NSCLC] or urothelial transitional cell carcinoma) were administered FdCyd (100 mg/m 2 ) and THU (350 mg/m 2 ) intravenously 5 days/week for 2 weeks, in 28-day cycles, and progression-free survival (PFS) rate and objective response rate (ORR) were evaluated. Blood specimens were collected for CTC analysis. Results Ninety-three eligible patients were enrolled (29 breast, 21 H&N, 25 NSCLC, and 18 urothelial). There were three partial responses. All strata were terminated early due to insufficient responses (H&N, NSCLC) or slow accrual (breast, urothelial). However, the preliminary 4-month PFS rate (42%) in the urothelial stratum exceeded the predefined goal—though the ORR (5.6%) did not. An increase in the proportion of p16-expressing cytokeratin-positive CTCs was detected in 69% of patients evaluable for clinical and CTC response, but was not significantly associated with clinical response. Conclusion Further study of FdCyd + THU is potentially warranted in urothelial carcinoma but not NSCLC or breast or H&N cancer. Increase in the proportion of p16-expressing cytokeratin-positive CTCs is a pharmacodynamic marker of FdCyd target engagement." @default.
• W3016741434 created "2020-04-24" @default.
• W3016741434 creator A5003847273 @default.
• W3016741434 creator A5003937547 @default.
• W3016741434 creator A5006657373 @default.
• W3016741434 creator A5015442703 @default.
• W3016741434 creator A5022641514 @default.
• W3016741434 creator A5027371881 @default.
• W3016741434 creator A5033078993 @default.
• W3016741434 creator A5034690406 @default.
• W3016741434 creator A5036091074 @default.
• W3016741434 creator A5040215906 @default.
• W3016741434 creator A5041200743 @default.
• W3016741434 creator A5043438658 @default.
• W3016741434 creator A5044239219 @default.
• W3016741434 creator A5045409088 @default.
• W3016741434 creator A5046042179 @default.
• W3016741434 creator A5046159625 @default.
• W3016741434 creator A5051681096 @default.
• W3016741434 creator A5057382599 @default.
• W3016741434 creator A5071469591 @default.
• W3016741434 creator A5071585351 @default.
• W3016741434 creator A5075327419 @default.
• W3016741434 creator A5079414611 @default.
• W3016741434 creator A5090468019 @default.
• W3016741434 date "2020-04-20" @default.
• W3016741434 modified "2023-10-13" @default.
• W3016741434 title "Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors" @default.
• W3016741434 cites W1208478680 @default.
• W3016741434 cites W1571540962 @default.
• W3016741434 cites W1573573597 @default.
• W3016741434 cites W1977706798 @default.
• W3016741434 cites W1982857584 @default.
• W3016741434 cites W1988720903 @default.
• W3016741434 cites W1999215232 @default.
• W3016741434 cites W2007757039 @default.
• W3016741434 cites W2016968778 @default.
• W3016741434 cites W2019607817 @default.
• W3016741434 cites W2027001392 @default.
• W3016741434 cites W2030947105 @default.
• W3016741434 cites W2034594496 @default.
• W3016741434 cites W2039957063 @default.
• W3016741434 cites W2040257851 @default.
• W3016741434 cites W2044052665 @default.
• W3016741434 cites W2082056146 @default.
• W3016741434 cites W2083780033 @default.
• W3016741434 cites W2086294283 @default.
• W3016741434 cites W2090450153 @default.
• W3016741434 cites W2099678391 @default.
• W3016741434 cites W2103749099 @default.
• W3016741434 cites W2104045516 @default.
• W3016741434 cites W2111178763 @default.
• W3016741434 cites W2111976640 @default.
• W3016741434 cites W2116483002 @default.
• W3016741434 cites W2127289529 @default.
• W3016741434 cites W2138114387 @default.
• W3016741434 cites W2138689567 @default.
• W3016741434 cites W2145750252 @default.
• W3016741434 cites W2148064779 @default.
• W3016741434 cites W2148631701 @default.
• W3016741434 cites W2148998801 @default.
• W3016741434 cites W2150958601 @default.
• W3016741434 cites W2152278540 @default.
• W3016741434 cites W2157037706 @default.
• W3016741434 cites W2161704074 @default.
• W3016741434 cites W2164562676 @default.
• W3016741434 cites W2167522449 @default.
• W3016741434 cites W2171855608 @default.
• W3016741434 cites W2261448069 @default.
• W3016741434 cites W2340189072 @default.
• W3016741434 cites W2441743520 @default.
• W3016741434 cites W2551420967 @default.
• W3016741434 cites W2560591127 @default.
• W3016741434 cites W2572628969 @default.
• W3016741434 cites W2605034121 @default.
• W3016741434 cites W2606001457 @default.
• W3016741434 cites W2755044288 @default.
• W3016741434 cites W2792487615 @default.
• W3016741434 cites W2806195669 @default.
• W3016741434 cites W2808109470 @default.
• W3016741434 cites W2886315248 @default.
• W3016741434 cites W2889482450 @default.
• W3016741434 cites W84924379 @default.
• W3016741434 cites W1519644050 @default.
• W3016741434 doi "https://doi.org/10.1007/s00280-020-04073-5" @default.
• W3016741434 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7188725" @default.
• W3016741434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32314030" @default.
• W3016741434 hasPublicationYear "2020" @default.
• W3016741434 type Work @default.
• W3016741434 sameAs 3016741434 @default.
• W3016741434 citedByCount "13" @default.
• W3016741434 countsByYear W30167414342020 @default.
• W3016741434 countsByYear W30167414342021 @default.
• W3016741434 countsByYear W30167414342022 @default.
• W3016741434 countsByYear W30167414342023 @default.
• W3016741434 crossrefType "journal-article" @default.
• W3016741434 hasAuthorship W3016741434A5003847273 @default.
• W3016741434 hasAuthorship W3016741434A5003937547 @default.

• next